P&PMed (Shanghai) Biotechnology

P&PMed (Shanghai) Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic and inflammatory diseases. The company leverages a proprietary structure-based drug design (SBDD) platform to develop next-generation small molecule and peptide therapeutics targeting G protein-coupled receptors (GPCRs). Its lead programs focus on the incretin pathway, including GLP-1, GIP, and Glucagon receptor agonists for the treatment of obesity and type 2 diabetes. P&PMed aims to provide differentiated treatment options with improved efficacy and safety profiles compared to existing injectable biologics.